BridgeBio Oncology Therapeutics, Inc. financial data

Symbol
BBOT on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1065% %
Debt-to-equity -46% % -1359%
Return On Equity 83% %
Return On Assets -13% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79,988,687 shares
Common Stock, Shares, Outstanding 79,196,710 shares
Entity Public Float $163,520,000 USD
Common Stock, Value, Issued $8,000 USD
Weighted Average Number of Shares Outstanding, Basic 43,491,085 shares 392100%
Weighted Average Number of Shares Outstanding, Diluted 43,491,085 shares 392100%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $35,052,000 USD 96%
General and Administrative Expense $16,262,379 USD 696%
Operating Income (Loss) $33,425,379 USD -150%
Nonoperating Income (Expense) $10,708,831 USD 89%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $33,059,488 USD -158%
Earnings Per Share, Basic -1.03 USD/shares 100%
Earnings Per Share, Diluted -1.03 USD/shares 100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $408,741,000 USD
Marketable Securities, Current $59,544,000 USD
Cash, Cash Equivalents, and Short-term Investments $468,300,000 USD
Assets, Current $476,010,000 USD 23213%
Property, Plant and Equipment, Net $827,000 USD
Operating Lease, Right-of-Use Asset $2,440,000 USD
Other Assets, Noncurrent $5,384,000 USD
Assets $484,793,000 USD 152%
Accounts Payable, Current $3,650,000 USD
Accrued Liabilities, Current $1,783,561 USD 7544%
Liabilities, Current $35,712,000 USD 28088%
Operating Lease, Liability, Noncurrent $2,381,000 USD
Liabilities $38,093,000 USD 575%
Accumulated Other Comprehensive Income (Loss), Net of Tax $36,000 USD
Retained Earnings (Accumulated Deficit) $317,770,000 USD -8933%
Stockholders' Equity Attributable to Parent $446,700,000 USD
Liabilities and Equity $484,793,000 USD 152%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $734,642 USD -19%
Net Cash Provided by (Used in) Financing Activities $186,461,597 USD
Net Cash Provided by (Used in) Investing Activities $184,000,000 USD
Common Stock, Shares Authorized 500,000,000 shares
Common Stock, Shares, Issued 79,196,710 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $408,873,000 USD 1903%
Operating Lease, Liability $2,887,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $44,772,000 USD -171%
Lessee, Operating Lease, Liability, to be Paid $3,407,000 USD
Operating Lease, Liability, Current $506,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Two $730,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $705,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $520,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year Three $755,000 USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 100%
Lessee, Operating Lease, Liability, to be Paid, Year Four $782,000 USD
Additional Paid in Capital $764,426,000 USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $1,425,000 USD 86%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%